Giant cell myocarditis: A rare cardiovascular manifestation in a patient with systemic lupus erythematosus

Lupus

Volumn 14, Issue 2, 2005, Pages 166-169

  Chung, L ^a   Berry, G J ^a   Chakravarty, Eliza F ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Congestive heart failure; Giant cell myocarditis; Immunosuppression; Lupus myocarditis; Systemic lupus erythematosus

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; CREATINE KINASE; CYCLOPHOSPHAMIDE; DNA ANTIBODY; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LEVOTHYROXINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; TROPONIN T;

ADULT; ARTICLE; CASE REPORT; DEATH; DEFIBRILLATOR; DISEASE DURATION; FEMALE; GIANT CELL; HEART ASSIST DEVICE; HEART FAILURE; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MYOCARDITIS; PATIENT REFERRAL; PRIORITY JOURNAL; PROGNOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; FATAL OUTCOME; FEMALE; GIANT CELLS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MYOCARDITIS;

EID: 14744281447     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203305lu2040cr     Document Type: Article

References (13)

1. Wijetunga M, Rockson S. Myocarditis in systemic lupus erythematosus. Am J Med 2002; 113: 419-423.
2. Fairfax M, Osbom T, Williams G, Tsai C, Moore T. Endomyocardial biopsy in patients with systemic lupus erythematosus. J Rheumatol 1988; 15: 593-596.
3. Rosenstein E, Zucker M, Kramer N. Giant cell myocarditis: most fatal of autoimmune diseases. Semin Arthritis Rheum 2000; 30: 1-16.
4. Davidoff R, Palacios I, Southern J, Fallon J, Newell J, Dec G. Giant cell versus lymphocytic myocarditis: a comparison of their clinical features and long-term outcomes. Circulation 1991; 83: 953-961.
5. Cooper L, Berry G, Shabetai R. Idiopathic giant-cell myocarditis - natural history and treatment. N Engl J Med 1997; 336: 1860-1866.
6. Mason J. Distinct forms of myocarditis. Circulation 1991; 83: 1110-1111.
7. Shields RC, Tazelaar HD, Berry GJ, Cooper LT. Sensitivity of right ventricular endomyocardial biopsy for idiopathic giant cell myocarditis. J Card Fail 2002; 8: 74-78.
8. Chan Y, Li E, Tam L, Chow L, Ng H. Intravenous cyclophosphamide improves cardiac dysfunction in lupus myocarditis. Scand J Rheumatol 2003; 32: 306-308.
9. Sherer Y, Levy Y, Shoenfeld Y. Marked improvement of severe cardiac dysfunction after one course of intravenous immunoglobulin in a patient with systemic lupus erythematosus. Clin Rheumatol 1999; 18: 238-240.
10. Chan T, Li F, Tang C et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 1156-1162.
11. Okura Y, Dec GW, Hare JM et al. A clinical and histopathological comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. J Am Coll Cardiol 2003; 41: 322-328.
12. Davies R, Veinot J, Smith S, Struthers C, Hendry P, Masters R. Giant cell myocarditis: clinical presentation, bridge to transplantation with mechanical circulatory support, and long-term outcome. J Heart Lung Transpl 2002; 21: 674-679.
13. Funkhouser J. Thymoma associated with myocarditis and the L.E.-cell phenomenon. N Engl J Med 1961; 264: 34-36.